Barclays reinstate coverage on Seattle Genetics (NASDAQ: SGEN) with a Overweight rating and a price target of $74.00.Analyst Geoff Meacham ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot New Coverage New Coverage